<i>Syzygium aromaticum</i>aqueous extract inhibits human neutrophils myeloperoxidase and protects mice from LPS-induced lung inflammation

Chniguir, Amina; Zioud, Fatma; Marzaioli, Viviana; El-Benna, Jamel; Bachoual, Rafik

doi:10.1080/13880209.2018.1557697

Cited by 30 publications

(22 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Knowing that VitB6 activates AMPK‐DOK3 pathway to suppress inflammation in macrophages, we next detected the in vivo effects of VitB6 on LPS‐induced lung inflammation in mice. The model of lung inflammation was induced by injection of LPS in WT and DOK3 −/− mice as described previously . Mice were challenged with an i.p.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Vitamin B6 inhibits macrophage activation to prevent lipopolysaccharide‐induced acute pneumonia in mice

Shan

Zhou

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

Macrophage activation participates in the pathogenesis of pulmonary inflammation. As a coenzyme, vitamin B6 (VitB6) is mainly involved in the metabolism of amino acids, nucleic acids, glycogen and lipids. We have previously reported that activation of AMP‐activated protein kinase (AMPK) produces anti‐inflammatory effects both in vitro and in vivo. Whether VitB6 via AMPK activation prevents pulmonary inflammation remains unknown. The model of acute pneumonia was induced by injecting mice with lipopolysaccharide (LPS). The inflammation was determined by measuring the levels of interleukin‐1 beta (IL‐1β), IL‐6 and tumour necrosis factor alpha (TNF‐α) using real time PCR, ELISA and immunohistochemistry. Exposure of cultured primary macrophages to VitB6 increased AMP‐activated protein kinase (AMPK) Thr172 phosphorylation in a time/dose‐dependent manner, which was inhibited by compound C. VitB6 downregulated the inflammatory gene expressions including IL‐1β, IL‐6 and TNF‐α in macrophages challenged with LPS. These effects of VitB6 were mirrored by AMPK activator 5‐aminoimidazole‐4‐carboxamide ribonucleoside (AICAR). However, VitB6 was unable to inhibit LPS‐induced macrophage activation if AMPK was in deficient through siRNA‐mediated approaches. Further, the anti‐inflammatory effects produced by VitB6 or AICAR in LPS‐treated macrophages were abolished in DOK3 gene knockout (DOK3−/−) macrophages, but were enhanced in macrophages if DOK3 was overexpressed. In vivo studies indicated that administration of VitB6 remarkably inhibited LPS‐induced both systemic inflammation and acute pneumonia in wild‐type mice, but not in DOK3−/− mice. VitB6 prevents LPS‐induced acute pulmonary inflammation in mice via the inhibition of macrophage activation.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The model of lung inflammation was induced by injection of LPS in WT and DOK3 −/− mice as described previously. 27 Mice were challenged with an i.p. injection of VitB6 (20 mg/kg) followed by LPS (0.5 mg/kg) injection ( Figure S4A).…”

Section: Vitb6 Prevents Acute Pneumonia In Wt Mice But Not In Dok3mentioning

confidence: 99%

Vitamin B6 inhibits macrophage activation to prevent lipopolysaccharide‐induced acute pneumonia in mice

Shan

Zhou

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…LPS-induced lung inflammation was also relieved with clove aqueous extract and eugenol through reduction of tumor necrosis factor (TNF)-a and inhibition of NF-kB signaling, as well as improvement in alveolar damage (Magalhaes et al, 2010;Chniguir et al, 2019).…”

Section: Clove (Syzygium Aromaticum (L) Merr and Lmperry)mentioning

confidence: 99%

An Evaluation of Traditional Persian Medicine for the Management of SARS-CoV-2

Bahramsoltani

Rahimi

2020

Front. Pharmacol.

View full text Add to dashboard Cite

A new coronavirus causing severe acute respiratory syndrome (SARS-CoV-2) has emerged and with it, a global investigation of new antiviral treatments and supportive care for organ failure due to this life-threatening viral infection. Traditional Persian Medicine (TPM) is one of the most ancient medical doctrines mostly known with the manuscripts of Avicenna and Rhazes. In this paper, we first introduce a series of medicinal plants that would potentially be beneficial in treating SARS-CoV-2 infection according to TPM textbooks. Then, we review medicinal plants based on the pharmacological studies obtained from electronic databases and discuss their mechanism of action in SARS-CoV-2 infection. There are several medicinal plants in TPM with cardiotonic, kidney tonic, and pulmonary tonic activities, protecting the lung, heart, and kidney, the three main vulnerable organs in SARS-CoV-2 infection. Some medicinal plants can prevent “humor infection”, a situation described in TPM which has similar features to SARS-CoV-2 infection. Pharmacological evaluations are in line with the therapeutic activities of several plants mentioned in TPM, mostly through antiviral, cytoprotective, anti-inflammatory, antioxidant, and anti-apoptotic mechanisms. Amongst the primarily-introduced medicinal plants from TPM, rhubarb, licorice, garlic, saffron, galangal, and clove are the most studied plants and represent candidates for clinical studies. The antiviral compounds isolated from these plants provide novel molecular structures to design new semisynthetic antiviral agents. Future clinical studies in healthy volunteers as well as patients suffering from pulmonary infections are necessary to confirm the safety and efficacy of these plants as complementary and integrative interventions in SARS-CoV-2 infection.

show abstract

“…IC 50 : 8.4 μg/mlMoradi et al (2018) Aqueous extract decreases neutrophil count and proteins leakage into bronchoalveolar lavage fluid. Dose: 200 mg/kgChniguir et al (2019) C2.40 Terminalia chebula Retz./Halala/Combretaceae/ Fruits…”

mentioning

confidence: 99%

Indian Medicinal Plants and Formulations and Their Potential Against COVID-19–Preclinical and Clinical Research

et al. 2021

View full text Add to dashboard Cite

The cases of COVID-19 are still increasing day-by-day worldwide, even after a year of its first occurrence in Wuhan city of China. The spreading of SARS-CoV-2 infection is very fast and different from other SARS-CoV infections possibly due to structural differences in S proteins. The patients with severe diseases may die due to acute respiratory distress syndrome (ARDS) caused by systemic inflammatory reactions due to the excessive release of pro-inflammatory cytokines and chemokines by the immune effector cells. In India too, it is spreading very rapidly, although the case fatality rate is below 1.50% (https://www.statista.com), which is markedly less than in other countries, despite the dense population and minimal health infrastructure in rural areas. This may be due to the routine use of many immunomodulator medicinal plants and traditional AYUSH formulations by the Indian people. This communication reviews the AYUSH recommended formulations and their ingredients, routinely used medicinal plants and formulations by Indian population as well as other promising Indian medicinal plants, which can be tested against COVID-19. Special emphasis is placed on Indian medicinal plants reported for antiviral, immunomodulatory and anti-allergic/anti-inflammatory activities and they are categorized for prioritization in research on the basis of earlier reports. The traditional AYUSH medicines currently under clinical trials against COVID-19 are also discussed as well as furtherance of pre-clinical and clinical testing of the potential traditional medicines against COVID-19 and SARS-CoV-2. The results of the clinical studies on AYUSH drugs will guide the policymakers from the AYUSH systems of medicines to maneuver their policies for public health, provide information to the global scientific community and could form a platform for collaborative studies at national and global levels. It is thereby suggested that promising AYUSH formulations and Indian medicinal plants must be investigated on a priority basis to solve the current crisis.

show abstract

Syzygium aromaticumaqueous extract inhibits human neutrophils myeloperoxidase and protects mice from LPS-induced lung inflammation

Cited by 30 publications

References 44 publications

Vitamin B6 inhibits macrophage activation to prevent lipopolysaccharide‐induced acute pneumonia in mice

Vitamin B6 inhibits macrophage activation to prevent lipopolysaccharide‐induced acute pneumonia in mice

An Evaluation of Traditional Persian Medicine for the Management of SARS-CoV-2

Indian Medicinal Plants and Formulations and Their Potential Against COVID-19–Preclinical and Clinical Research

Contact Info

Product

Resources

About